Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 19/20 | 0.68 |
| ▸ | WDR77 | Q9BQA1 | 18/20 | 0.68 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833951 | 0.92 | PRMT5 (0.81) | PRMT5WDR77 | |
| SCHEMBL15834077 | 0.92 | PRMT5 (0.81) | PRMT5WDR77 | |
| SCHEMBL15834007 | 0.92 | PRMT5 (0.81) | PRMT5WDR77 | |
| SCHEMBL19957747 | 0.81 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15935363 | 0.81 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15935366 | 0.81 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL19957941 | 0.79 | PRMT5 (0.64) | PRMT5WDR77 | |
| SCHEMBL19957761 | 0.74 | PRMT5 (0.57) | PRMT5WDR77 | |
| SCHEMBL15826022 | 0.74 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL19287694 | 0.73 | PRMT5 (0.76) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732072-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160137631-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9221794-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20140228360-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | PRMT5, PRMT1, PRMT7 | PRMT5 1/4885WDR77 18/4885CARM1 8/4885 |
| US-20140228360-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885CARM1 8/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 54/4885CARM1 8/4885 |
| US-20160137631-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885CARM1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.